Renovaro Inc., a leader in TechBio specializing in diagnostics, drug discovery, and cancer therapies, has announced an expedited trial date in its lawsuit against Predictive Oncology Inc. The litigation, filed on May 9, 2025, in the Delaware Court of Chancery, seeks to enforce a binding merger agreement initially executed on January 1, 2025. Renovaro alleges that Predictive Oncology breached provisions of the agreement by conducting a public offering of $545,000 in securities and attempting to terminate the agreement unilaterally without meaningful negotiations. Renovaro is pursuing specific performance, injunctive relief, and damages, with the case currently pending under Case No. 2025-0509.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。